消水方联合托伐普坦治疗肝炎肝硬化顽固性腹水临床研究*

doi:10.3969/j.issn.1672-5069.2016.02.017

Abstract

Zhu Junfeng, Qian Ping'an, Fan Xingliang. Efficacy of XiaoShuiFang and tolvaptan in the treatment of patients with hepatitis B-induced liver cirrhosis complicated by refractory ascites[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(2): 192-195.

References

[1] 中华医学会传染病与寄生虫学分会和肝病学分会.病毒性肝炎防治方案.中华传染病杂志,2000,18（8）：324-329.
[2] Moore KP,Wong F,Gine SP,et a1.The management of ascites in cirrhosis;report on the consensus conference of the International Ascites Club. Hepatology,2003,38（1）：258-266.
[3] American Association for the Study of Liver Diseases（AASLD） Practice Guidelines:Management of adult patients with ascites due to cirrhosis:An update.Hepatology,2009,49（6）：2087-2107.
[4] 王吉耀.现代肝病治疗学.上海：上海医科大学出版社,1999：244.
[5] 中国中西医结合学会消化系统疾病专业委员会.肝硬化中西医结合诊治方案.现代消化及介入治疗,2005,10（2）：119-121.
[6] Schouten J,Michielsen PP. Treatment of cirrhotic ascites. Acta Gastroenterol Belg,2007,70（2）：217-222.
[7] European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites,spontaneous bacterial peritonitis,and hepatorenal syndrome in cirrhosis. J Hepatol,2010,53（3）：397-417.
[8] Runyon BA.Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012.Hepatology,2013,57（4）：1651-1653.
[9] Arroyo V,Gines P,Gerbes AL,et al. Definition and diagnostic criteria of refractory scites and hepatorenal syndrome in cirrhosis. Hepatology,1996,23（1）：164-176.
[10] 祝峻峰,陶运生,姜国良,等.超滤浓缩回输对肝硬变顽固性腹水的治疗作用.中医药临床杂志,2005,17（2）：161-162.
[11] Salerno F,Merli M,Riggio O,et al. Randomized controlled study of TIPS versus paracentesis plus albumin in cirrhosis with severe ascites.Hepatology,2004,40（3）：629-635.
[12] 徐晓光,蔡洪培.肝硬化低钠血症的研究进展.中华消化杂志,2002,22（9）：560-561.
[13] Wong VW,Chim AM,Wong GL,et al. Performance of the new MELD-NA score in predicting 3-month and 1-year mortality in Chinese patients with chronic hepatitis B. Liver Transpl,2007,13（9）：1228-1235.
[14] 黄莺,张春红.心力衰竭合并低钠血症患者的临床特征分析及其疗效观察.实用心脑肺血管病杂志,2013,21（4）：34-40.
[15] 贾友宏,许莉,田蕾.口服托伐普坦片对男性健康志愿者的药效学作用及其对血电解质的影响.中国新药杂志,2008,17（2）：160-164.
[16] Schweiger TA,Zdanowicz MM.Vasopressin-receptor antagonists in heart failure.Am J Heal Sys Pharm,2008,25:807-817.
[17] Schrier RW,Gross P,Gheorghiade M,et al. SALT investigators. Tolvaptan,a selective oral vasopressin V2-receptor antagonist for hyponatremia. N Engl J Med,2006,355（20）：2099-2112.
[18] Okita K,Sakaida I,Okada M,et al. A multicenter,open-label,dose-ranging study to exploratively evaluate the efficacy,safety,and dose-response of tolvaptan in patients with decompensated liver cirrhosis. J Gastroenterol,2010,45（9）：979-987.
[19] 郑俊福,张鑫,赵文敏,等.托伐普坦治疗顽固性腹水疗效及安全性分析.实用肝脏病杂志,2014,17（6）：623-627.
[20] 高司成,夏莉,赵钢,等.“水臌贴”敷脐联合西药治疗脾肾阳虚型肝硬化腹水随机安慰剂对照临床研究.上海中医药杂志,2015,49（2）：28-30.
[21] 祝峻峰,王灵台.王灵台教授运用补肾法防治慢性乙型肝炎“三部曲”.中西医结合肝病杂志,2014,24（6）：357-359.

Efficacy of XiaoShuiFang and tolvaptan in the treatment of patients with hepatitis B-induced liver cirrhosis complicated by refractory ascites

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Zhuang Ying, Lin Zhihui.. Clinical manifestations and diagnosis of portal vein thrombosis [J]. Journal of Practical Hepatology, 2019, 22(6): 765-767.
[2]	Yang Caiyong, Chen Na, Li Kui, et al.. Clinical significance of peripheral blood Treg and Th17 cells in patients with chronic hepatitis C and hepatitis C-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(6): 868-871.
[3]	Zhu Yage, Liu Jinfeng.. Therapeutic efficacy of adenosine methionine and glycyrrhizin combination in treatment of patients with alcoholic cirrhosis and its effect on serum BGP levels [J]. Journal of Practical Hepatology, 2019, 22(6): 872-875.
[4]	Wu Dan Ma Xiangying.. Insulin resistance,carotid atherosclerosis and left ventricular function in patients with NAFLD-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(6): 876-879.
[5]	He Zhi’an, Yu Liping, Lai Jiangqiong, et al.. Evaluation of varices bleeding and portal vein thrombosis by ARFI in patients with cirrhosis and esophagogastric varices [J]. Journal of Practical Hepatology, 2019, 22(6): 888-891.
[6]	Wang Yueyuan, Wang Yan, Zhang Dandan. Short-term efficacy of terlipressin and octreotide combination in treatment of cirrhotic patients complicated by hepatorenal syndrome [J]. Journal of Practical Hepatology, 2019, 22(5): 684-687.
[7]	Zhang Mei, Shi Xiuying, Li Linjuan, et al. Hepatic expression of interferon inducible protein -10 in patients with hepatitis B liver cirrhosis and hepatogenic diabetes mellitus [J]. Journal of Practical Hepatology, 2019, 22(5): 688-691.
[8]	Dan Zhuyongji, Liu Zhilan, Lu Yanyan, et al. Efficacy of endoscopic sequential variceal 1igation plus sclerotherapy in treatment of patients with hepatitis B-induced liver cirrhosis complicated by esophageal gastric varices bleeding [J]. Journal of Practical Hepatology, 2019, 22(5): 692-695.
[9]	Huang Hanjun, Lu Fengrong, Zhang Can. Clinical value of MRI scanning based on exchange hemodynamics model in evaluating liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(5): 696-699.
[10]	Zhao Fangfang, Zhai Yongzhen, Feng Guohe. Efficacy and safety of autologous peripheral blood stem cell transplantation in patients with hepatitis B cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(5): 700-703.
[11]	Chen Shan, Zhuang Huashuai, Xing Yixi, et al. Preventive application of meropenem in patients with liver cirrhosis complicated by upper gastrointestinal bleeding [J]. Journal of Practical Hepatology, 2019, 22(5): 704-707.
[12]	Xu Qilin, Hao Shaohuan, Ran Bo. Risk factors of portal vein thrombosis after splenectomy in patients with liver cirrhosis and portal hypertension [J]. Journal of Practical Hepatology, 2019, 22(5): 708-711.
[13]	Jin Lianghong, Li Xingjie, Guan Hongbo, et al. Clinical value of dual-energy CT iodine quantification combined with dynamic contrast-enhanced MRI in evaluating hepatic hemodynamics and liver functions in patients with hepatitis B liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(5): 712-715.
[14]	Bian Xinqu, Chen Jie, Liu Yanmin, et al. Serum thyroid hormone level changes in patients with primary biliary cholangitis receiving ursodeoxycholic acid therapy [J]. Journal of Practical Hepatology, 2019, 22(5): 716-719.
[15]	Zhang Zhicheng, Yuan Guangqi, Mo Chanjun. Impact of blood supply on efficacy of hepatic artery embolization in treatment of patients with hepatic hemangioma [J]. Journal of Practical Hepatology, 2019, 22(5): 736-739.